Breaking News

Calvert Labs, Particle Sciences In Drug Services Pact

March 15, 2013

Aims to streamline preclinical drug development

Calvert Laboratories and Particle Sciences have formed an alliance to offer a streamlined solution aimed at expediting preclinical drug development. This partnership aims to alleviate formulation challenges that often delay entry into preclinical testing by aligning formulation and preclinical experts to identify the problem and provide a solution more quickly. Particle Sciences will work to develop a formulation specifically aimed at achieving the desired exposure levels to allow Calvert Labs to carry out the testing component of the project.

Particle Sciences has expertise in nano-milling and lipidic formulation technologies, and can manufacture under sterile conditions and handle highly potent compounds and controlled substances. Calvert Labs offers an array of preclinical services.

Calvert Labs’ president and chief scientific officer, Charles B. Spainhour, V.M.D, Ph.D., said, “Formulation is often one of the most significant challenges our clients’ face. The sooner we can resolve any issues, the more quickly we can help them advance their program forward.”

Mark Mitchnick, M.D., chief executive officer of Particle Sciences, said, “No single group has the in-depth expertise in both formulation and toxicology needed to tackle this. Through this combined effort, under a single scope of work, our clients are getting a very valuable service unavailable anywhere else.”

Related Contract Manufacturing:

Related Packaging:

blog comments powered by Disqus
  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments

  • The Role of Alliances in Modern Drug Development

    The Role of Alliances in Modern Drug Development

    Dr. Claire Madden-Smith, Senior Vice President, Juniper Pharma Services||September 8, 2016
    Combining expertise to get drug candidates through development

  • Limiting APIs in Manufacturing Effluent

    Limiting APIs in Manufacturing Effluent

    Joan Tell, Robert Drinane, Bruce Naumann, Jessica Vestel, and Gregory Gagliano, Merck & Co., Inc.||June 2, 2016
    An approach for setting limits on pharmaceuticals discharged in manufacturing effluent